A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

This study is testing a CAR-T cell therapy — where immune cells are engineered to attack a protein called CD19 on cancer cells — for patients with relapsed or treatment-resistant B-cell blood cancers, including leukemia and lymphoma. **You may be eligible if...** - You have been confirmed to have CD19-positive B-cell leukemia (B-ALL) or B-cell lymphoma that has relapsed or is not responding to treatment - Your disease has not responded to standard chemotherapy, or came back quickly, or has relapsed more than once **You may NOT be eligible if...** - You have a serious active infection (including HIV or active hepatitis B/C) - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding - You have other serious medical conditions that make you ineligible for this treatment Talk to your doctor to see if this trial is right for you.